Yes @GazD this is good news indeed. And it’s enough to get them through the interim results of the phase 3. Assuming they are as good as all the results to date, that’s hopefully all that’s needed for it to run hard or be gobbled up by big pharma. Good interim results would also make the options more likely to be in the money, which would then likely provide the rest of the funding required for completion of the phase 3.

Given the notes are convertible at 75 c + (vs the current share price in the 30c range), the US financier wouldn’t have provided the funding, if they didn’t think that was likely.

I was also happier with the way Paul Rennie and his team communicated on the call today, so while I don't expect perfectly smooth sailing from here, hopefully we have some tailwinds now...